Table 4.
Concentrations of Amphotericin B in Lung Tissue, Epithelial Lining Fluid, Pulmonary Alveolar Macrophages, and Peripheral Blood Monocytes After Once-daily Dosing for 8 Days
| Drug | Dose (mg/kg) | Mean Concentration ± Standard Deviation in: | ||||
|---|---|---|---|---|---|---|
| Lung Tissue (µg/g) | Epithelial Lining Fluid (µg/mL) | Pulmonary Alveolar Macrophages (µg/mL) | Peripheral Blood Monocytes (µg/mL) | Plasma (µg/mL) | ||
| Deoxycholate amphotericin B | 1 | 2.71 ± 1.22 | 0.44 ± 0.13 | 8.92 ± 2.84 | 1.20 ± 0.83 | 0.34 ± 0.07 |
| Amphotericin B colloidal dispersion | 5 | 6.29 ± 1.17 | 0.68 ± 0.27 | 5.43 ± 1.75 | 2.44 ± 1.90 | 0.37 ± 0.12 |
| Amphotericin B lipid complex | 5 | 16.26 ± 1.62 | 0.90 ± 0.28 | 89.1 ± 37 | 0.74 ± 0.42 | 0.24 ± 0.08 |
| Liposomal amphotericin B | 5 | 6.32 ± 0.57 | 2.28 ± 1.43 | 7.52 ± 2.50 | 1.51 ± 0.78 | 26.4 ± 4.99 |
Twenty-four hours after dosing. All values represent the means ± standard deviation from 3 to 7 rabbits in each dosing group. Plasma, concurrent plasma concentrations. Between-group comparisons using Dunn’s correction for multiple comparisons revealed significant differences in lung tissue concentrations between deoxycholate amphotericin B (DAmB)– and amphotericin B lipid complex (ABLC)–treated animals (P < .01), in epithelial lining fluid concentrations between DAmB– and Liposomal amphotericin B–treated animals (P < .01), and in pulmonary alveolar macrophages concentrations between amphotericin B colloidal dispersion– and ABLC–treated animals (P < .05). Reproduced with permission from Groll AH et al. Antimicrob Agents Chemother 2006; 50:3418–23 [127].